» Articles » PMID: 11501970

Transmembrane Proteases As Disease Markers and Targets for Therapy

Overview
Specialties Biochemistry
Biology
Date 2001 Aug 15
PMID 11501970
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Transmembrane proteases (i.e. membrane-associated proteases, ectoproteases) are present in a wide variety of tissues and cell types including endothelial, epithelial and hematopoietic cells. Natural and synthetic inhibitors have been characterized and have revealed that certain ectoenzymes are able to modulate bioactive peptide responses and to influence major biological events such as cell proliferation, survival and invasiveness. Dysregulated expression of some of them in human diseases triggers research on their role in pathophysiology, on their value as disease markers and as putative targets for therapy.

Citing Articles

Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.

Liu Q, Dong H, Zhao W, Zhang G, Li S, Xu Q ACS Med Chem Lett. 2021; 12(12):1932-1941.

PMID: 34917257 PMC: 8667313. DOI: 10.1021/acsmedchemlett.1c00504.


studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy.

Al-Mansoori L, Bashraheel S, Al Qahtani A, OConnor C, Elsinga P, Goda S Oncotarget. 2020; 11(6):619-633.

PMID: 32110281 PMC: 7021235. DOI: 10.18632/oncotarget.27478.


Aminopeptidase A initiates tumorigenesis and enhances tumor cell stemness via TWIST1 upregulation in colorectal cancer.

Chuang H, Jiang J, Yang M, Wang H, Li M, Tsai C Oncotarget. 2017; 8(13):21266-21280.

PMID: 28177885 PMC: 5400582. DOI: 10.18632/oncotarget.15072.


Exploring ligand dissociation pathways from aminopeptidase N using random acceleration molecular dynamics simulation.

Liu Y, Tu G, Lai X, Kuang B, Li S J Mol Model. 2016; 22(10):236.

PMID: 27624165 DOI: 10.1007/s00894-016-3105-y.


Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells.

Bouchet S, Tang R, Fava F, Legrand O, Bauvois B Oncotarget. 2014; 5(18):8211-22.

PMID: 25246708 PMC: 4226678. DOI: 10.18632/oncotarget.1788.